CG Invites

We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine


  • Indication
    MRSA (Methicillin-resistant Staphylococcus aureus)
  • Development stage
    • Nilofabicin met all efficacy endpoints in a U.S. Phase 2 clinical study for treatment of MRSA.


Nilofabicin's differentiation
  1. 01

    Specific inhibition of the Fab l target, which is expressed only in the S. aureus family group

  2. 02

    기존의 MRSA용 항생제들이 보이는 내성 및 다양한 부작용 없음

  3. 03

    Showed superior non-clinical efficacy results when compared to top MRSA drugs Zyvox and Cubicin

  4. 04

    U.S. Phase 2 clinical study results showed a 91 percent cure rate in MRSA patients within three days and a 100 percent cure for all MRSA patients within two weeks

Fab I (Fatty acid biosynthesis I)
  • Enoyl-acyl carrier protein reductase is present in bacteria. This protein holds a vital role regarding bacterial fatty acid synthesis and is essential for survival.
  • When Fab I is suppressed using Nilofabicin, MRSA strains are selectively killed to treat infectious diseases without side effects to the human body.